These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8174197)

  • 41. Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney.
    Domitrović R; Cvijanović O; Pugel EP; Zagorac GB; Mahmutefendić H; Škoda M
    Toxicology; 2013 Aug; 310():115-23. PubMed ID: 23770416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
    DeWoskin RS; Riviere JE
    Toxicol Appl Pharmacol; 1992 Feb; 112(2):182-9. PubMed ID: 1311464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck.
    Holding JD; Lindup WE; van Laer C; Vreeburg GC; Schilling V; Wilson JA; Stell PM
    Br J Clin Pharmacol; 1992 Jan; 33(1):75-81. PubMed ID: 1540494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vitamin E mitigates cisplatin-induced nephrotoxicity due to reversal of oxidative/nitrosative stress, suppression of inflammation and reduction of total renal platinum accumulation.
    Darwish MA; Abo-Youssef AM; Khalaf MM; Abo-Saif AA; Saleh IG; Abdelghany TM
    J Biochem Mol Toxicol; 2017 Jan; 31(1):1-9. PubMed ID: 27550472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
    Boven E; Westerman M; van Groeningen CJ; Verschraagen M; Ruijter R; Zegers I; van der Vijgh WJ; Giaccone G
    Br J Cancer; 2005 May; 92(9):1636-43. PubMed ID: 15841080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is there cumulative or delayed toxicity from cis-platinum?
    Chiuten D; Vogl S; Kaplan B; Camacho F
    Cancer; 1983 Jul; 52(2):211-4. PubMed ID: 6683119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
    Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
    Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term studies of cisplatin-induced reductions in porcine renal functional reserve.
    Robbins ME; Bywaters TB; Jaenke RS; Hopewell JW; Matheson LM; Tothill P; Whitehouse E
    Cancer Chemother Pharmacol; 1992; 29(4):309-15. PubMed ID: 1537078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Clinical observations and pharmacokinetic analyses.
    Lerza R; Esposito M; Vannozzi M; Bottino GB; Bogliolo G; Pannacciulli I
    Cancer; 1994 Jan; 73(1):79-84. PubMed ID: 8275441
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of streptozotocin (STZ)-induced diabetes, dextrose diuresis and acetone on cisplatin nephrotoxicity in Fischer 344 (F344) rats.
    Scott LA; Madan E; Valentovic MA
    Toxicology; 1990; 60(1-2):109-25. PubMed ID: 2107603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistence of sisomicin and gentamicin in renal cortex and medulla compared with other organs and serum of rats.
    Fabre J; Rudhardt M; Blanchard P; Regamey C
    Kidney Int; 1976 Dec; 10(6):444-9. PubMed ID: 1011538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of buthionine sulphoximine, glutathione and methimazole on the renal disposition of cisplatin and on cisplatin-induced nephrotoxicity in rats: pharmacokinetic-toxicodynamic analysis.
    Hanada K; Mukasa Y; Nomizo Y; Ogata H
    J Pharm Pharmacol; 2000 Dec; 52(12):1483-90. PubMed ID: 11197076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine.
    Saad SY; Najjar TA; Daba MH; Al-Rikabi AC
    Chemotherapy; 2002; 48(6):309-15. PubMed ID: 12673106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
    Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
    Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.